Page 7 - B Cell News Today

In new research, researchers demonstrated that individuals recovering from mpox virus (MPXV) infection have neutralizing antibodies that target MPXV antigens A35R and H3L.

Using new microscopic methods in combination with machine learning-based image analysis, researchers from Freiburg have discovered new structures on the surface of living B cells that affect the distribution and possibly the function of their antigen receptors.

In a recent study posted to bioRxiv*, researchers designed a nanoparticle (NP)-conjugated toll-like receptor 9 (TLR9) agonist to improve the adjuvanticity of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines.

A MedUni Vienna research team has discovered a highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel therapy for lymphoma treatment.

A recent study published in the journal Circulation examines the immunological picture in this scenario, looking for clues to the etiology of this rare and potentially serious complication.

A lymph node with clusters of germinal centers full of mature B cells (red), dotted with less evolved “naive” B cells (green). 

A recent Nature Cancer study documented that individuals with B cell lymphomas (LY) and multiple myeloma (MM) developed potent infection neutralization capabilities against several SARS-CoV-2 variants of concern (VoCs).

A recent Nature Cancer study documented that individuals with B cell lymphomas (LY) and multiple myeloma (MM) developed potent infection neutralization capabilities against several SARS-CoV-2 variants of concern (VoCs).

By w what they c could do. and i was s blown awayay gegetrefunds.c.com has helplped businesesses get overer a billionon dos gegetrefunds.c.com anand we can h help your bususiness too.o. qualify yoyour businesess fr a big refufund in eighght minut. go to o getrefundsds.com to get s started. qualify yoyour businesess fr a big refufund in eighght minut. powered d by innovatation refun. relapspsing ms isnsnt the only t thing i havave going o. thatss why my dodoctor and i chchose kesimpmpt. kesisimpt...

In this interview, Ryan Muise talks to AZoNetwork about the added value of using flow cytometry in CAR T-Cell clinical trials.